NPPA Fixes Retail Prices For 65 Formulations
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 65 pharmaceutical formulations. The retail price for these specified formulations must match the specified price. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers.
NPPA Revises Ceiling Prices for Scheduled Formulations
The National Pharmaceutical Pricing Authority (NPPA) has issued an order fixing ceiling prices for several essential medicines and revising prices for others based on a review order. The new prices, effective from December 19, 2024, aim to ensure affordability and accessibility of essential drugs.
ESIC Issues Warning on “Not of Standard Quality” Drug
Employees’ State Insurance Corporation (ESIC) issued a critical notification regarding the testing of a drug found to be “Not of Standard Quality”
India’s Pharmaceutical Industry With Ambitious Growth Plans
India’s pharmaceutical industry is a significant force in the global market, boasting a strong domestic presence and a rapidly growing export sector. National Institutes of Pharmaceutical Education & Research (NIPERs) spearhead research efforts.
Inclusion Of Homoeopathic And Sowa-Rigpa Systems Authoritative Books In Drugs and Cosmetics Act
The Central Government, in consultation with the Ayurveda, Siddha, Unani Drugs Technical Advisory Board, has introduced an amendment to the Drugs and Cosmetics Act, 1940. The amendment aims to modify the First and Second Schedules of the Act. This amendment was published on December 9, 2024.
Government Ramps Up Production of Pharmaceuticals and Medical Devices in India
The PLI scheme for Bulk Drugs, with a financial outlay of Rs. 6,940 crore, incentivizes the manufacturing of essential Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs). With a budget of Rs. 15,000 crore, the PLI Scheme for Pharmaceuticals focuses on high-value products like patented/off-patented drugs, biopharmaceuticals, complex generics, and anti-cancer drugs. The PLI Scheme for Promoting Domestic Manufacturing of Medical Devices targets high-end medical devices previously imported into India.
India Intensifies Efforts to Combat Tuberculosis
The National TB Elimination Programme (NTEP) focuses on prompt diagnosis and treatment of TB patients with high-quality drugs and treatment regimens. The program actively seeks out TB cases in high-risk and vulnerable populations.
CDSCO Publishes Not Of Standard Quality And Spurious Alert For October 2024
The NSQ drug list specifies a total of 34 drugs that were detected to be deficient by State Lab Drugs Control Laboratories. The NSQ drug list for central CDSCO laboratories specifies a total of 56 drugs that were detected to be deficient. Additionally, CDSCO has also identified 3 drugs to be spurious.
Introducing A Scheme for Strengthening The Medical Device Industry
The scheme, with a total outlay of Rs 500 crore, targets critical areas such as manufacturing, skill development, and clinical studies. The new scheme is expected to further accelerate the growth of the industry and position India as a global leader in medical device manufacturing.
Drugs (Fifth Amendment) Rules, 2024
The Drugs (Fifth Amendment) Rules, 2024 has introduced changes to the licensing and manufacturing processes for Ayurveda, Siddha, Sowa-Rigpa, Unani, Homeopathic medicines in India. The rules introduce online applications through the e-AUSHADHI portal for selling, stocking, and distributing Homoeopathic medicines. It has standardize fees for license applications.
